Abstract
1. Mexiletine was given to 156 patients by intravenous or oral routes of administration. 2. There was great interpatient variation in kinetics and plasma concentrations with both routes of administration. 3. The mean volume of distribution was 6.63 l/kg. The mean plasma elimination haf-life after chronic oral therapy was 11.31 h. 4. Plasma concentrations between 0.75 and 2.00 microgram/ml were usually effective. Within this therapeutic range severe side effects were uncommon. 5. Plasma concentrations within this range were achieved in 72% of patients when doses of 10--14 mg-1 kg-1 day were given orally.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Campbell N. P., Kelly J. G., Shanks R. G., Chaturvedi N. C., Strong J. E., Pantridge J. F. Mexiletine (Kö 1173) in the management of ventricular dysrhythmias. Lancet. 1973 Aug 25;2(7826):404–407. doi: 10.1016/s0140-6736(73)92271-x. [DOI] [PubMed] [Google Scholar]
- Campbell R. W., Dolder M. A., Prescott L. F., Talbot R. G., Murray A., Julian D. G. Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction. Lancet. 1975 Jun 7;1(7919):1257–1260. doi: 10.1016/s0140-6736(75)92548-9. [DOI] [PubMed] [Google Scholar]
- Greenblatt D. J., Kock-Weser J. Drug therapy. Clinical Pharmacokinetics (first of two parts). N Engl J Med. 1975 Oct 2;293(14):702–705. doi: 10.1056/NEJM197510022931406. [DOI] [PubMed] [Google Scholar]
- Kelly J. G. Measurement of plasma mexiletine concentrations. Postgrad Med J. 1977;53 (Suppl 1):48–49. [PubMed] [Google Scholar]
- Kelly J. G., Nimmo J., Rae R., Shanks R. G., Prescott L. F. Spectrophotofluorometric and gas-liquid chromatographic methods for the estimation of mexiletine (Kö 1173) in plasma and urine. J Pharm Pharmacol. 1973 Jul;25(7):550–553. doi: 10.1111/j.2042-7158.1973.tb09155.x. [DOI] [PubMed] [Google Scholar]
- Pottage A. Oral dosage schedules for mexiletine. Postgrad Med J. 1977;53 (Suppl 1):155–157. [PubMed] [Google Scholar]
- Prescott L. F., Pottage A., Clements J. A. Absorption, distribution and elimination of mexiletine. Postgrad Med J. 1977;53 (Suppl 1):50–55. [PubMed] [Google Scholar]
- Talbot R. G., Julian D. G., Prescott L. F. Long-term treatment of ventricular arrhythmias with oral mexiletine. Am Heart J. 1976 Jan;91(1):58–65. doi: 10.1016/s0002-8703(76)80435-8. [DOI] [PubMed] [Google Scholar]
- Talbot R. G., Nimmo J., Julian D. G., Clark R. A., Neilson J. M., Prescott L. F. Treatment of ventricular arrhythmias with mexiletine (Kö 1173). Lancet. 1973 Aug 25;2(7826):399–404. doi: 10.1016/s0140-6736(73)92270-8. [DOI] [PubMed] [Google Scholar]
- Wilson C., Pantridge J. F. St-segment displacement and early hospital discharge in acute myocardial infarction. Lancet. 1973 Dec 8;2(7841):1284–1288. doi: 10.1016/s0140-6736(73)92868-7. [DOI] [PubMed] [Google Scholar]